Navigation Links
Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
Date:10/26/2007

Promising pre-clinical results support advance to clinical study for third combination chemotherapy from Celator based on the company's proprietary

CombiPlex(TM) technology platform.

PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today announced positive results from preclinical studies to evaluate the optimal ratio of irinotecan and cisplatin to deliver synergistic benefit against a range of tumor cell lines in vitro. The study further worked to develop an effective formulation to maintain the optimal ratio of these drugs in vivo. Results were presented this week in a poster presentation at the AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA.

In the study, combinations of irinotecan and cisplatin were applied to a panel of 20 human and murine tumor cell lines enriched with lung tumor carcinomas in vitro to identify the ratios most likely to deliver synergistic benefit. The combination exhibited strong drug ratio dependent synergy. Using Celator's proprietary CombiPlex technology, researchers then engineered a combination of irinotecan and cisplatin in liposomes to maintain a synergistic 7:1 molar ratio following intravenous administration. The product, known as CPX-571, was compared to a combination of irinotecan and cisplatin administered as free drugs, and to monotherapy with each drug agent administered in a liposome formulation in mice implanted with human solid tumor xenografts. In all tumor models tested, CPX-571 showed a high degree of anti-tumor activity and significantly improved efficacy as compared to the combination of free drugs and to the individual liposomal drug agents.

"In this study we were able to identify the optimal ratio of irinotecan and cisplatin to use in combination chemotherapy and then combine the drugs in a formulation able to maintain that ratio in animal models. Along with our progress in developing CPX-1, currently in a Phase 2 study as a therapy for colorectal cancer, and CPX-351, currently in a Phase 1 study for patients with leukemia, these promising results, indicating broad potential anti-tumor activity for CPX-571, represent another validation of Celator's CombiPlex technology platform," said Andrew Janoff, Ph.D., CEO of Celator.

CombiPlex(TM), Celator's proprietary technology platform, identifies the optimal ratio of drugs to use in combination therapies and then incorporates an advanced nanoparticle delivery system to maintain those optimal ratios when drugs are administered to patients.

"Based on these findings, there is significant support to advance CPX-571 to clinical development in the treatment of small cell lung cancers and potentially for use in treating other types of cancer," said Arthur Louie, M.D., Celator's chief medical officer.

ABOUT CELATOR

Celator Pharmaceuticals, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1, currently in a Phase 2 trial as a treatment option for colorectal cancer; CPX-351, currently in a Phase 1 trial as a treatment for leukemia (for information visit http://www.clinicaltrials.gov and search "Celator"); CPX 571, now positioned to advance to Phase 1 trial and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
4. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
5. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
6. RT-PCR Primers for the Study of Apoptosis
7. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
10. Medical College receives $377K to study brain disease
11. Kauffman study shows consistent entrepreneurial growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):